leadf
logo-loader
viewAcasti Pharma Inc

Acasti Pharma expects top-line results on heart disease therapy by year's end

Acasti Pharma Inc (NASDAQ:ACST) CEO Jan D'Alvise tells Proactive Investors that the Quebec-based biopharma is expecting Phase 3 top-line results by the end of 2019 for its krill oil-derived drug candidate CaPre, which treats severe hypertriglyceridemia, a contributor to heart disease.

D'Alvise says she's excited as she expects the study to show not only a significant triglyceride reduction but also a unique effect on improving glucose metabolism levels in diabetic patients.

Quick facts: Acasti Pharma Inc

Price: 0.29 CAD

TSX-V:ACST
Market: TSX-V
Market Cap: $28.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 26/11/19

2 min read